chronic obstructive pulmonary diseasestreatmenttiotropium bromideхронические обструктивные болезни легкихлечениетиотропиума бромид1.Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Executive summary. Updated 2003 (www.goldcopd.com)2.Celli B. R., Benditt J. O., Albert R. K. Chronic obstructive pulmonary disease. In: Albert R., Spiro S., Jett J. (Eds) Comprehensive respiratory medicine. London: Mosby; 2001. 37.1 - 37.24.3.Iqbal A., Schloss S., George D. et al. Worldwide guidelines for chronic obstructive pulmonary disease: A comparison of diagnosis and treatment recommendations. Respirology 2002; 7: 233-239.4.Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad. Med. J. 1975; 51 (suppl. 7): 13-20.5.Chapman K. R. History of anticholinergic treatment in airways disease. In: Gross N. J. (Ed.) Anticholinergic therapy in obstructive airways disease. London: Franklin Scientific Publications; 1993. 9-17.6.Barnes P. J. Tiotropium bromide. Expert. Opin. Invest. Drugs 2001; 10: 733-740.7.Hvizdos K. M., Goa K. L. Tiotropium bromide. Drugs 2002; 62: 1195-1203.8.Barnes P. J. (3-Agonists, anticholinergics, and other nonsteroid drugs. In: Albert R., Spiro S., Jett J. (Eds) Comprehensive respiratory medicine. London: Mosby; 2001. 34.1-34.10.9.Hansel Т. Т., Barnes P. J. Tiotropium bromide: a novel oncedaily anticholinergic bronchodilator for the treatment of COPD. Drugs of Today 2002; 38: 585-600.10.Barnes P. J. Muscarinic receptor subtypes in airways. Life Sci. 1993; 52: 521-528.11.Eglen R. M., Choppin A., Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol. Sci. 2001;22:409-414.12.Maesen F. P. V., Smeets J. J., Costongs Ma. A. L. et al. Ba 679 Br, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study in COPD. Eur. Respir. J. 1993; 6: 1031-1036.13.Disse В., Speck G. A., Rominger K. L. et al. Tiotropium (Spiriva) mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64: 457-464.14.Barnes P. J. The pharmacological properties of tiotropium. Chest 2000; 117 (suppl. 2): 63-68.15.Disse В., Reichi R., Speck G. et a!. A novel long-acting anticholinergic bronchodilator. Life Sci. 1993; 52: 537-544.16.Haddad E. В., Мак J. С., Barnes P. J. et al. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiograhic maping. Mol. Pharmacol. 1994; 45: 899-907.17.Nisar M., Euris J. E., Pearson M. G. et al. Acute bronchodilator trials in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1992; 146: 555-559.18.O'Donnel D. E., Lam M., Webb K. A. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 1557-1565.19.Casaburi R., Mahler D. A., Jones P. W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.20.Vincken W., van Noord J. A., Greethorst A. P. et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiptropium. Eur. Respir. J. 2002; 19: 209-216.21.Belman M. J., Botnick W. C., Shin J. W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967-975.22.Anthonisen N. R., Connett J. E., Kiley J. P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J. A. M. A. 1994; 272: 1497-1505.23.Leusch A., Eichhorn В., Muller G. et al. Pharmacokinetics and tissue distribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm. Drug Dispos. 2001; 22: 199-212.24.Maesen F. P. V., Smeets J. J., Sledsens T. J. H. et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator. A pharmacodynamic study in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1995; 8: 1506- 1513.25.van Noord J. A., Smeets J. J., Custers F. L. et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 639- 644.26.Littner M. R., llowite J. S., Tashkin D. P. et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1136-1142.27.van Noord J. A., Bantje T. A., Eland M. E. et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000; 55: 289-294.28.Casaburi R., Serby W., Menjoge S. S. et al. The spirometric efficacy of once daily dosing with tiotropium in stable COPD. Am. J. Respir. Crit. Care Med. 1999; 159: A524.29.Donohue J. F., van Noord J. A., Babeman E. D. et al. A 6month, placebo-controlled comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.30.Tashkin D., Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003; 123: 1441-1449.31.Busasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.32.Anzueto A., Menjoge S. S., Kesten S. Changes in FEV, over time in 1-year clinical trials of tiotropium in COPD. In: Proceedings of the Annual meeting of the American Thoracic Society (ATS). San Francisco; 2001.33.Oostenbrink J. В., Rutten-van Molken M., Anton S. et al. A Markov model based on COPD disease severity to analyze the results for a tiotropium trials. Eur. Respir. J. 2002; 20 (suppl. 38): 125S (P 833).34.Chodosh S., Flanders J. S., Kesten S. et al. Effective delivery of particles with the HandiHaler Dry Powder Inhalation System over a range of chronic obstructive pulmonary disease severity. J. Aerosol. Med. 2001; 14: 309-315.35.Rand С. S., Nides M., Cowles M. K. et al. Long-term metereddose inhaler adherence in a clinical trial: The Lung Health Study Research Group. Am. J. Respir. Crit. Care Med. 1995; 152: 580-588.36.Canadian Thoracic Society COPD Guidelines: summary of highlights for family doctors. Can. Respir. J. 2003; 10: 183- 186.